BMJ investigation reveals AstraZeneca’s billion-dollar heart drug built on flawed data
A damning BMJ investigation has blown open a scandal at the heart of modern cardiology, revealing how AstraZeneca’s billion-dollar blockbuster ticagrelor may have reached patients through manipulated data, missing evidence, and phantom investigators in clinical trials that regulators failed to properly scrutinise.
